|
|
|
|
| |
 Oxford Gene Technology (OGT) has successfully completed processing more than 20,000 samples that have been generated by the Wellcome Trust Case Control Consortium (WTCCC), the world’s largest CNV study involving a collaboration of 24 leading human geneticists. The project analysed DNA samples from patients to identify genetic ariants that play a role in various human diseases, including bipolar disorder, Crohn’s disease, coronary artery disease, type 1 and 2 diabetes, and hypertension. OGT processed over 20,000 samples in 20 weeks, using state-of-the-art automatedprocessing to achie exceptional data quality from wholegenome human CNV-focussed microarrays developed by Agilent. Over 40 quality control checks havebeen performed and recorded for each sample during the workflow, producing documented evidence of the excellent QC metrics that have been met.
|
 Printer Friendly version |
|
|
| |
|
 |  | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
 Visit
the Laboratory News archive
Visit
the Laboratory Science and Research
Features archive
Visit
the Laboratory Products, Equipment
and Supplies archive
|
|
|
|
|
|
